FDA Inspection
LEESAR, INCLEESAR, INC – FDA Inspection, Oct 29, 2021
Record Details
This FDA Inspection record concerns LEESAR, INC, with an inspection on October 29, 2021, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- LEESAR, INC
- Inspection Date
- October 29, 2021
- Product Type
- Drugs
View Company Profile
ID · 32d81905-7783-4221-af38-992e00ec4a4b
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1155647
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Enforcement
- Untitled Letter
FDA Citations
4- 21 CFR 211.186(b)(7)Theoretical Yield and Percentages
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.110(a)Written in-process control procedures
- Outsourcing facility, compounded drug report follow up
Full citation text and observation details available on the Dashboard.
Other FDA inspections of LEESAR, INC
5| Date | Classification | Office | Project area |
|---|---|---|---|
| September 23, 2026 | Not classified | Florida District Office | |
| July 18, 2025 | NAI | Florida District Office | Postmarket Assurance: Medical Devices |
| May 9, 2025 | VAI | Florida District Office | Drug Quality Assurance |
| July 12, 2017 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 8, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for LEESAR, INC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.